jueves, 19 de diciembre de 2024

Weekly Nab-Paclitaxel Shows Modest Advantage in High-Risk HR+/HER2– Early Breast Cancer Christos Evangelou, MSc, PhD December 19, 2024

https://www.medscape.com/viewarticle/weekly-nab-paclitaxel-shows-modest-advantage-high-risk-hr-2024a1000ojm

No hay comentarios:

Publicar un comentario